Infectious Disease Therapeutics Market: By Drug class, By disease indication, By Distribution channel, and Region Forecast 2020-2031

Infectious Disease Therapeutics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug class (Anti-Bacterial, Anti-Viral, Anti-Parasite, Anti-Fungal, Others), By disease indication (HIV/AIDS, Influenza, Hepatitis, Malaria, TB, Others), By Distribution channel (Hospital Pharmacy, Retail Pharmacy, Others), and Region Forecast 2020-2031

Infectious disease therapeutics market size was valued at US$ 150.9 billion in 2024 and is expected to reach US$ 255.3 billion by 2031, growing at a significant CAGR of 7.8% from 2025-2031. Infectious diseases are caused by organisms, such as bacteria, virus, fungi or parasites. Many organisms live in our body but few of them cause diseases. These infectious diseases are transmitted from one individual to other either by direct or indirect contact. The drugs used for infectious diseases are antibiotics, antiviral, and antiparasitic, among others. Infectious disease therapeutics acts directly on organisms or helps the body system to fight infections. Infectious diseases include HIV, malaria, tuberculosis, hepatitis, and influenza, among others. Market players focus on mergers, acquisitions and collaborations to increase revenue share in the market.

For instance, in August 2016, Pfizer acquired AstraZeneca's late-stage small molecule anti-infectives business for development and commercialization outside the U.S. In addition, market players investing on research and development to introduce new drugs and to strengthen their position in the market. Some of the pipeline anti-infectives include avycaz (ceftazidime and avibactam), bictegravir (Anti HIV), cabotegravir (Anti HIV). Patent expiry of blockbuster anti-infectives such as Tamiflu, cubicin and ambisome are expected to negatively effect the infectious disease therapeutics industry.

Key Developments

  • In July 2017, Gilead's oral tablet was approved by U.S. FDA for treatment of adults with chronic hepatitis C virus
  • In March 2015, U.S. Food and Drug Administration approved cresemba (isavuconazonium sulfate), a novel antifungal drug for treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections
  • In December 2014, Sanofi Pasteur announces FDA approval of fluzone intradermal quadrivalent (Influenza Vaccine) for adults.

Global Infectious Disease Therapeutics Market Summary

Study Period

2025-2031

Base Year

2024

CAGR

7.8%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Infectious Disease Therapeutics Market Dynamics

Infectious disease therapeutics market is driven by the growing prevalence rates of infectious diseases, increased healthcare expenditure and increased funding of governments on prevention and management of infectious diseases. In addition, increased geriatric population and use of direct acting antiviral drugs are fuelling the growth of infectious diseases therapeutics market. However, patent expiry of many infectious disease drugs and increase number of generic alternatives hindering the market revenue of market.

Global Infectious Disease Therapeutics Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2025-2031

Market Size in 2024

US$ 150.9 billion

Market Size in 2031

US$ 255.3 billion

Market CAGR

7.8%

By Drug Class

  • Anti-Bacterial
  • Anti-Viral
  • Anti-Parasite
  • Anti-Fungal
  • Others

By Disease Indication

  • HIV/AIDS
  • Influenza
  • Hepatitis
  • Malaria
  • TB
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Key Features of the Report

  • The infectious disease therapeutics market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

Frequently Asked Questions

Infectious disease therapeutics market size was valued at US$ 150.9 billion in 2024 and is expected to reach US$ 255.3 billion by 2031, growing at a significant CAGR of 7.8%.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Infectious Disease Therapeutics Market Introduction 
2.1.Global Infectious Disease Therapeutics Market  - Taxonomy
2.2.Global Infectious Disease Therapeutics Market  - Definitions
2.2.1.Drug Class
2.2.2.Disease Indication
2.2.3.Distribution Channel
2.2.4.Region
3.Global Infectious Disease Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Infectious Disease Therapeutics Market Analysis, 2020 - 2024 and Forecast 2025 - 2031
4.1.  Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Infectious Disease Therapeutics Market  By Drug Class, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
5.1. Anti-Bacterial
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Anti-Viral
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Anti-Parasite
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Anti-Fungal
5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Others
5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6.Global Infectious Disease Therapeutics Market  By Disease Indication, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
6.1. HIV/AIDS
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Influenza
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Hepatitis
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Malaria
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. TB
6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Others
6.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
7.Global Infectious Disease Therapeutics Market  By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
7.1. Hospital Pharmacy
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacy
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Infectious Disease Therapeutics Market  By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Infectious Disease Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
9.1. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Anti-Bacterial
9.1.2.Anti-Viral
9.1.3.Anti-Parasite
9.1.4.Anti-Fungal
9.1.5.Others
9.2.  Disease Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.HIV/AIDS
9.2.2.Influenza
9.2.3.Hepatitis
9.2.4.Malaria
9.2.5.TB
9.2.6.Others
9.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacy
9.3.2.Retail Pharmacy
9.3.3.Others
9.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Infectious Disease Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Anti-Bacterial
10.1.2.Anti-Viral
10.1.3.Anti-Parasite
10.1.4.Anti-Fungal
10.1.5.Others
10.2.  Disease Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.HIV/AIDS
10.2.2.Influenza
10.2.3.Hepatitis
10.2.4.Malaria
10.2.5.TB
10.2.6.Others
10.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacy
10.3.2.Retail Pharmacy
10.3.3.Others
10.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Infectious Disease Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Anti-Bacterial
11.1.2.Anti-Viral
11.1.3.Anti-Parasite
11.1.4.Anti-Fungal
11.1.5.Others
11.2.  Disease Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.HIV/AIDS
11.2.2.Influenza
11.2.3.Hepatitis
11.2.4.Malaria
11.2.5.TB
11.2.6.Others
11.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacy
11.3.2.Retail Pharmacy
11.3.3.Others
11.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Infectious Disease Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Anti-Bacterial
12.1.2.Anti-Viral
12.1.3.Anti-Parasite
12.1.4.Anti-Fungal
12.1.5.Others
12.2.  Disease Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.HIV/AIDS
12.2.2.Influenza
12.2.3.Hepatitis
12.2.4.Malaria
12.2.5.TB
12.2.6.Others
12.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacy
12.3.2.Retail Pharmacy
12.3.3.Others
12.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Infectious Disease Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Anti-Bacterial
13.1.2.Anti-Viral
13.1.3.Anti-Parasite
13.1.4.Anti-Fungal
13.1.5.Others
13.2.  Disease Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.HIV/AIDS
13.2.2.Influenza
13.2.3.Hepatitis
13.2.4.Malaria
13.2.5.TB
13.2.6.Others
13.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacy
13.3.2.Retail Pharmacy
13.3.3.Others
13.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.GlaxoSmithKline Plc (U.K.)
14.2.2.Johnson & Johnson Services, Inc. (U.S.)
14.2.3.Merck & Co, Inc. (U.S.)
14.2.4.Pfizer Inc. (U.S.)
14.2.5.Novartis AG. (Switzerland)
14.2.6.AbbVie Inc. (U.S.)
14.2.7.Astellas Pharma Inc. (Japan)
14.2.8.AstraZeneca (U.K.)
14.2.9.Auritec Pharmaceuticals Inc. (U.S.)
14.2.10.Bayer AG (Germany)
14.2.11.Modified Polymer Components, Inc. (Bristol-Myers Squibb) (U.S.)
14.2.12.Chimerix Inc. (U.S.)
14.2.13.Eli Lilly and Company (U.S.)
14.2.14.Isis Pharmaceuticals (U.S.)
14.2.15.Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma) (Japan)
14.2.16.Sanofi S.A. (France)
14.2.17.Gilead Sciences (U.S.)
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • GlaxoSmithKline Plc (U.K.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Merck & Co, Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • Novartis AG. (Switzerland)
  • AbbVie Inc. (U.S.)
  • Astellas Pharma Inc. (Japan)
  • AstraZeneca (U.K.)
  • Auritec Pharmaceuticals Inc. (U.S.)
  • Bayer AG (Germany)
  • Modified Polymer Components, Inc. (Bristol-Myers Squibb) (U.S.)
  • Chimerix Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • Isis Pharmaceuticals (U.S.)
  • Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma) (Japan)
  • Sanofi S.A. (France)
  • Gilead Sciences (U.S.)

Related Industry Reports